A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00240006

Enrollment

307

Registered

2005-10-17

Start date

2006-01-31

Completion date

2007-09-30

Last updated

2011-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Copaxone®, Shared Solutions®

Brief summary

To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who receive support only from Shared Solutions®.

Interventions

PROCEDUREShared Solutions® plus MS Center v. Shared Solutions®

Copaxone

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Males or females, 18 years of age or older. 2. Diagnosed with Relapsing Remitting Multiple Sclerosis (relapses accepted). 3. Beginning or restarting therapy with Glatiramer Acetate (Copaxone®). 4. Willing and able to complete all procedures and evaluations related to the study. 5. Willing to provide informed consent.

Exclusion criteria

1. Taking any other immunomodulatory or immunosuppressant therapy in conjunction with Copaxone®. 2. Has a significant medical illness other than MS that may interfere with the assessment of endpoints or the subject's participation in the trial for the full duration of the study. 3. Any situation that the investigator or nurse (if not the investigator) feel may interfere with participation in the study. 4. Pregnant or trying to become pregnant, or breast feeding during the study. 5. Previously participated in this study or another clinical research study in the past 30 days.

Design outcomes

Primary

Measure	Time frame
Adherence rate of Copaxone therapy by procedural intervention	90 days

Secondary

Measure	Time frame
Compliance of treatment, positive experience of treatment, levels of depression, proportion of time spent, self injection competency ratings, and the risk of non-adherence/non-compliance	90 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026